2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 3060

Development and Implementation of a Question-Based Tool Promoting Learning of Relevant Epidemiology and Biostatistics in Rheumatology: The Critical Literature Assessment Skills Support – Rheumatology (CLASS-Rheum) Pilot
Abstract Number: 3061

Future Challenges in Pediatric Rheumatology: The Role of Graduate Medical Education (GME)
Abstract Number: 3062

Use of Script Concordance Testing to Evaluate the Efficacy of a Web-Based Module on Gout: Three Years of Experience
Abstract Number: 3063

Learning Rheumatology through Fellow-Generated Questions: The Rheumatology Image of the Week Project
Abstract Number: 3064

From Art to Science: A Mobile App for Point-of-Care Relevance Determination for the Musculoskeletal Exam
Abstract Number: 3065

Mortality in Patients with Rheumatoid Arthritis and Interstitial Lung Disease Treated with First Line TNFi or Rituximab Therapies
Abstract Number: 3066

Risk of Incident Cancer with Biologic and Tofacitinib Therapy in Rheumatoid Arthritis
Abstract Number: 3067

Treatment Decisions Following Diagnosis of Cancer during TNFi Inhibitor Treatment in Patients with Rheumatoid Arthritis: Results from the BSRBR-RA
Abstract Number: 3068

Smoking and Excess Weight Attenuate Rate of Improvement over First 3 Years in Early RA
Abstract Number: 3069

Weight Loss in the Early Rheumatoid Arthritis Period Is Associated with Subsequent Increased Mortality in RA Patients and Matched Comparators: Evidence Against an RA-Specific Obesity Paradox
Abstract Number: 3070

Effect of Sarcopenia, Subcutaneous Adipose Tissue and Abdominal Visceral Fat on Mortality Risk of Community-Dwelling Older Adults: A Population-Based Prospective Cohort Study
Abstract Number: 3071

Recombinant Human Proteoglycan-4 (rhPRG4) Inhibits Monosodium Urate (MSU) Crystal Phagocytosis By Human Macrophages and Resultant Inflammatory Response
Abstract Number: 3072

Increased Platelet Reactivity in Gout: Relationship to Tophus Burden and Colchicine Use
Abstract Number: 3073

Non-Additive Interaction of the Glucokinase Regulatory Protein and APOBEC1 Complementation Factor Loci with Alcohol Consumption to Influence the Risk of Gout
Abstract Number: 3074

Population-Specific Association Between ABCG2 Variants and Tophaceous Disease in People with Gout

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].